AI Article Synopsis
- - Over the last ten years, researchers have recognized a link between APOBEC3 enzymes and cancer mutations, highlighting the need for tools to find inhibitors of these enzymes.
- - The team developed a new assay called RADD (Real-time APOBEC3-mediated DNA Deamination) that allows for quick setup and real-time fluorescent monitoring of enzyme activity, providing valuable insights into its kinetics.
- - This assay enhances the current methods for studying APOBEC3 enzymes and can easily be scaled up for high-throughput screening to discover new inhibitors.
Article Abstract
Over the past decade, the connection between APOBEC3 cytosine deaminases and cancer mutagenesis has become increasingly apparent. This growing awareness has created a need for biochemical tools that can be used to identify and characterize potential inhibitors of this enzyme family. In response to this challenge, we have developed a Real-time APOBEC3-mediated DNA Deamination (RADD) assay. This assay offers a single-step set-up and real-time fluorescent read-out, and it is capable of providing insights into enzyme kinetics and also offering a high-sensitivity and easily scalable method for identifying APOBEC3 inhibitors. This assay serves as a crucial addition to the existing APOBEC3 biochemical and cellular toolkit and possesses the versatility to be readily adapted into a high-throughput format for inhibitor discovery.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11100776 | PMC |
| http://dx.doi.org/10.1101/2024.05.11.593688 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!